차세대 약물 접합체 시장 : 차세대 약물 접합체 유형별, 표적 리간드타입별, 페이로드 유형별, 주요 지역별 - 업계 동향과 세계 예측(- 2035년)

Next Generation Drug Conjugates Market by Type of Next Generation Drug Conjugates, Type of Targeting Ligand, Type of Payload, and Key Geographical Regions: Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,943,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,126,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,335,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 26,042,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 차세대 약물 접합체 시장 규모는 2035년까지 예측 기간 동안 15.07%의 연평균 복합 성장률(CAGR)로 확대되어 현재 33억 달러에서 2035년까지 154억 7,000만 달러로 성장할 것으로 예상됩니다.

차세대 약물 접합체는 비면역원성, 구조적 안정성, 우수한 임상 프로파일, 페이로드의 표적 전달, 제한된 부작용, 투과성, 더 깊은 세포 침투성으로 인해 암을 포함한 희귀질환 적응증에 대한 표적치료제로서 유망한 가능성을 가지고 있습니다. 항체 약물 접합체(ADC)와 마찬가지로 펩타이드, 아미노당, 지질, 저분자 등 다양한 비항체 표적 약물을 사용하면서도 우수한 임상적 효과와 안정성을 자랑하고 있습니다. 기존 약물 대신 올리고뉴클레오티드, 안티센스 올리고뉴클레오티드, Si-RNA, 약물, 방사성 핵종 등의 페이로드를 표적 전달에 사용합니다. 펩타이드 약물 접합체, 펩타이드 수용체 방사성 핵종 치료, GalNac 복합체, Si-RNA 복합체 등이며, 모두 고형암, 대사 이상, 혈액 질환 등의 질환에 효과가 있는 것으로 입증되었습니다.

USFDA는 Lutathera(R), Pluvicto(R), Givlaari(R), Oxlumo(R), Leqvio(R), Amvuttra(R)를 포함한 6가지 차세대 약물 접합체를 치료제로 승인했습니다. 이번 승인은 이러한 첨단 치료법의 임상적 성과와 다양한 질환에 대한 잠재력을 강조하고 있습니다. 지속적인 기술 혁신, 유망한 임상 결과, 신속한 승인, 협력적 노력으로 인해 차세대 약물 접합체 시장은 예측 기간 동안 큰 성장을 보일 것으로 예상됩니다.

파이프라인에는 저분자, 펩타이드, 지질, 아미노당, 바이러스와 같은 입자를 치료 목적의 표적화 리간드로 삼는 200개 이상의 차세대 약물 접합체가 있습니다.

차세대 약물 접합체의 약 60%가 펩타이드를 표적 리간드로 사용하고 있으며, 대부분 암 질환 치료를 위한 임상시험에서 평가되고 있습니다. 다양한 차세대 약물 접합체의 안전성과 유효성을 평가하기 위해 지난 몇 년동안 260개 이상의 임상시험이 등록되었습니다. 최근 몇 년동안 효과적인 약물 접합체 개발을 위해 이 분야의 제휴 활동이 활발해지고 있습니다. 임상 효과의 부족이 약물 실패의 일반적인 이유이며, 임상시험의 55% 이상이 중단되었습니다. 개발 파이프라인에 대한 관심 증가와 유망한 임상 결과들로 인해 향후 10년간 연간 20% 이상 시장 성장이 예상됩니다.

세계의 차세대 약물 접합체 시장에 대해 조사했으며, 시장 개요와 함께 차세대 약물 접합체 유형별/표적 리간드 유형별/페이로드 유형별/주요 지역별 동향, 시장 진출 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 서문

제2장 주요 요약

제3장 서론

제4장 시장 구도

제5장 기업과 의약품 개요

제6장 임상시험 분석

제7장 파트너십 및 협업

제8장 학술 보조금 분석

제9장 출판물 분석

제10장 약제 실패 분석

제11장 성공 프로토콜 분석

제12장 시장 예측과 기회 분석

제13장 부록 1 : 표 형식 데이터

제14장 부록 2 : 기업 및 단체 리스트

LSH

영문 목차

영문목차

Next Generation Drug Conjugates Market: OVERVIEW

As per Roots Analysis, the global next generation drug conjugates market is estimated to grow from USD 3.3 billion in the current year to USD 15.47 billion by 2035, at a CAGR of 15.07% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Next Generation Drug Conjugates

• Peptide Receptor Radionuclide Therapy (Peptide Radionuclide Conjugate)
• Ligand Mediated RNAi Conjugate
• Ligand Conjugated Anti Sense Medicine
• Peptide Drug Conjugate

Type of Targeting Ligand

• Amino Sugar
• Lipid
• Peptide

Type of Payload

• Si-RNA
• Antisense Oligonucleotide
• Radionuclide
• Drug

Type of Therapy

• Monotherapy
• Combination Therapy

Route of Administration

• Intravenous
• Subcutaneous

Key Target Indications

• Gastroenteropancreatic Neuroendocrine Tumors
• Prostate Cancer
• Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases
• Hereditary Transthyretin Amyloidosis
• Atherosclerotic Cardiovascular Diseases
• Severe Hypertriglyceridemia
• Hereditary Angioedema
• Acute Hepatic Porphyria
• Primary Hyperoxaluria
• Heterozygous Familial Hypercholesterolemia
• Hemophilia
• Low-Risk Myelodysplastic Syndrome
• Myelofibrosis
• Alpha-1 Antitrypsin Deficiency Liver Disease
• Familial Chylomicronemia Syndrome

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

NEXT GENERATION DRUG CONJUGATES MARKET: GROWTH AND TRENDS

Owing to their non-immunogenic nature, structural stability, better clinical profile, targeted delivery of payload, limited side effects, permeability and deeper cellular penetration, next generation drug conjugates have emerged as viable targeted therapeutics for rare disease indications, including cancers. Similar to antibody drug conjugates (ADCs), these advanced versions boast superior clinical efficacy and stability while employing diverse non-antibody targeting agents, such as peptides, amino sugars, lipids, and small molecules. Instead of traditional drugs, they use payloads, such as oligonucleotides, antisense oligonucleotides, si-RNA, drugs, and radionuclides for targeted delivery. This fusion of targeting ligands and payloads has spawned various types of next generation drug conjugates, including peptide drug conjugates, peptide receptor radionuclide therapy, GalNac conjugates, si-RNA conjugates, all proving effective against diseases, such as solid tumors, metabolic disorders, and hematological disorders.

The USFDA has approved six next generation drug conjugates for therapeutic use, including Lutathera(R), Pluvicto(R), Givlaari(R), Oxlumo(R), Leqvio(R), and Amvuttra(R). These approvals underscore the clinical triumphs of these advanced therapies and their potential across a wide range of medical conditions. With ongoing innovation, promising trial outcomes, expedited approvals, and collaborative efforts, the market for next generation drug conjugates anticipates significant growth in the forecast period.

NEXT GENERATION DRUG CONJUGATES MARKET: KEY INSIGHTS

The report delves into the current state of the next generation drug conjugates market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. The pipeline features more than 200 next generation drug conjugates with small molecules, peptides, lipids, amino sugars and virus like particles as the targeting ligands for therapeutic purposes.

2. Close to 60% of the next generation drug conjugates use peptides as targeting ligands; of these, the majority are being evaluated in clinical trials for the treatment of oncological disorders.

3. Over 260 clinical trials have been registered in the past few years to evaluate the safety and efficacy of various next generation drug conjugates; majority of these studies have been conducted across sites in the US.

4. Over the past few years, partnership activity in this field has increased for the development of effective drug conjugate therapies.

5. Lack of clinical efficacy has been the common reason for drug failure, accounting for the discontinuation of more than 55% of clinical trials, while several non-drug related issues caused the failure of more than 30% of trials.

6. With growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 20%, during the next decade.

NEXT GENERATION DRUG CONJUGATES MARKET: KEY SEGMENTS

Ligand Mediated RNAi Conjugate Occupies the Largest Share of the Next Generation Drug Conjugates Market

Based on the type of next generation drug conjugates, the market is segmented into ligand mediated RNAi conjugate, peptide-radionuclide conjugate, ligand conjugated anti sense medicine and peptide drug conjugate. Currently, ligand mediated RNAi conjugate holds the maximum share of the next generation drug conjugates market. It is worth highlighting that the next generation drug conjugates for ligand conjugated anti sense medicine is likely to grow at a relatively higher CAGR.

Amino Sugar is Likely to Dominate the Next Generation Drug Conjugates Market in the Coming Decade

Based on the targeting ligand, the market is segmented into amino sugar, lipids and peptide. At present, peptide captures the highest portion of the next generation drug conjugates market. However, in the near future, the next generation drug conjugates market is likely to be driven by amino sugar.

Radionuclides Occupy the Largest Share of the Next Generation Drug Conjugates

Based on payload, the market is segmented into si-RNA, radionuclide, antisense oligonucleotide and drug. At present, radionuclide holds the maximum share of the next generation drug conjugates market. It is worth highlighting that the next generation drug conjugates for si-RNA is likely to grow at a relatively higher CAGR.

Combination Therapies are Likely to Dominate the Next Generation Drug Conjugates Market During the Forecast Period

Based on the type of therapy, the market is segmented into monotherapy and combination therapy. Currently, combination therapy holds the maximum share of the next generation drug conjugates market. This trend is unlikely to change in the coming decades.

Intravenous Route Occupies the Largest Share of the Next Generation Drug Conjugates Market

Based on the route of administration, the market is segmented into intravenous and subcutaneous. The intravenous mode of drug delivery captures the highest share of the current next generation drug conjugates market. However, the next generation drug conjugates market for subcutaneous route is likely to grow at a relatively higher CAGR in the coming decade.

The Hemophilia Segment is the Fastest Growing Segment of the Next Generation Drug Conjugates Market During the Forecast Period

Based on the key target disease indication, the market is segmented into gastroenteropancreatic neuroendocrine tumors, prostate cancer, leptomeningeal carcinomatosis caused by breast cancer brain metastases, hereditary transthyretin amyloidosis, atherosclerotic cardiovascular diseases, severe hypertriglyceridemia, hereditary angioedema, acute hepatic porphyria, primary hyperoxaluria, heterozygous familial hypercholesterolemia, hemophilia, low-risk myelodysplastic syndrome, myelofibrosis, alpha-1 antitrypsin deficiency liver disease and familial chylomicronemia syndrome. It is worth highlighting that, at present, prostate cancer holds a higher share of the next generation drug conjugates market. However, the next generation drug conjugates market for hemophilia is likely to grow at a relatively higher CAGR.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, and Asia-Pacific and the Rest of the World. The majority share is expected to be captured by players based in North America. It is worth highlighting that, over the years, the market in Asia-Pacific and the Rest of the World is expected to grow at a higher CAGR.

Example Players in the Next Generation Drug Conjugates Market

• Advanced Accelerator Applications
• Alnylam Pharmaceuticals
• Arrowhead Pharmaceuticals
• Dicerna Pharmaceuticals
• Geron Corporation
• Ionis Pharmaceuticals

NEXT GENERATION DRUG CONJUGATES MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the next generation drug conjugates market, focusing on key market segments, including [A] type of targeting ligand, [B] type of payload, [C] type of therapy, [D] route of administration, [E] target disease indication and [F] key geographical regions.
• Market Landscape: A comprehensive evaluation of next generation drug conjugates / next generation targeted therapeutics that are either approved or being evaluated in different stages of development, considering various parameters, such as [A] type of conjugate, [B] type of targeting ligand, [C] type of payload, [D] type of biological target, [E] mechanism of action, [F] stage of development, [G] phase of development, [H] type of therapy, [I] route of administration, [J] target disease indication, [K] therapeutic area and [L] target population. Further, the chapter includes information on various next generation drug conjugate developers, based on their [M] year of establishment, [N] company size, [O] location of headquarters and [P] most active players (in terms of number of drug candidates).
• Company Profiles: In-depth profiles of key industry players involved in the development of next generation drug conjugates, focusing on [A] company overviews, [B] product portfolio, [C] detailed information on the drug candidates which are either approved or are in phase III of clinical development, [D] recent developments and [E] an informed future outlook.
• Clinical Trials: Examination of completed, ongoing, and planned clinical studies of various drug conjugates based on parameters like [A] trial registration year, [B] trial phase, [C] trial status, [D] enrolled patient population, [E] type of sponsor, [F] age group, [G] most active industry players, [H] leading drug candidate, [I] primary purpose, [J] therapeutic area and [K] key geographical regions.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2018, covering acquisitions, research and development agreements, product development and commercialization agreements, platform / technology licensing agreement, service agreements, clinical trial agreements, joint ventures and others.
• Academic Grant Analysis: A comprehensive evaluation of various grants that have been awarded to research institutes engaged in conducting research related to next generation drug conjugates, since 2018, based on various important parameters, such as [A] year of grant award, [B] amount awarded, [C] funding institute center, [D] support period, [E] type of grant application, [F] purpose of grant award, [G] activity code, [H] study section involved, [I] popular NIH departments (based on number of grants awarded), [J] prominent program officers, [K] leading recipient organizations and [L] key regions.
• Publication Analysis: An in-depth analysis of scientific articles focused on next generation drug conjugates based on [A] year of publication, [B] type of publication, [C] type of conjugate, [D] target indication, [C] copyright holders, [D] focus area, [E] leading publishers and [F] key journals (in terms of number of articles published and impact factor).
• Drug Failure Analysis: An in-depth analysis of next generation drug conjugates that failed to progress to later stages of development, based on various relevant parameters, such as trial status of discontinuation, trial phase of discontinuation, average trial year, type of therapy, target indication and reason for drug failure.
• Success Protocol Analysis: An insightful success protocol analysis of recently approved and commercialized next generation drug conjugates, based on several relevant parameters, such as dosing frequency, drug efficacy, drug exclusivity, drug designation, fatality rate, geographical reach, intra-class competition, line of treatment, prevalence, price, type of therapy, and existing competition among developers.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Next Generation Drug Conjugates Market Overview
• 1.2. Key Market Insights
• 1.3. Scope of the Report
• 1.4. Research Methodology
• 1.5. Frequently Asked Questions
• 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Overview of Next Generation Drug Conjugates
• 3.2. Key Historical Events
• 3.3. Structure of Next Generation Drug Conjugates
• 3.4. Biochemical Interaction and Mechanism of Action
• 3.5.Key Target Indications
• 3.6. Advantages of Next Generation Drug Conjugates
• 3.7 Challenges associated with Next Generation Drug Conjugates
• 3.8. Future Perspectives

4. MARKET LANDSCAPE

• 4.1. Methodology
• 4.2. Next Generation Drug Conjugates: List of Therapies
  • 4.2.1. Analysis by Type of Conjugate
  • 4.2.2. Analysis by Type of Targeting Ligand
  • 4.2.3. Analysis by Type of Payload
  • 4.2.4. Analysis by Biological Target
  • 4.2.5. Analysis by Mechanism of Action
  • 4.2.6. Analysis by Stage of Development
  • 4.2.7. Analysis by Phase of Development
  • 4.2.8. Analysis by Type of Therapy
  • 4.2.9. Analysis by Route of Administration
  • 4.2.10. Analysis by Target Disease Indication
  • 4.2.11. Analysis by Therapeutic Area
  • 4.2.12. Analysis by Type of Conjugate and Stage of Development
  • 4.2.13. Analysis by Type of Conjugate and Target Population
• 4.3. Next Generation Drug Conjugates: Developer Landscape
  • 4.3.1. Analysis by Year of Establishment
  • 4.3.2. Analysis by Company Size
  • 4.3.3. Analysis by Location of Headquarters (Region-wise)
  • 4.3.4. Analysis by Location of Headquarters (Country-wise)
  • 4.3.5.Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
  • 4.3.6. Most Active Players: Analysis by Number of Drug Candidates

5. COMPANY AND DRUG PROFILES

• 5.1. Advanced Accelerator Applications
  • 5.1.1. Company Overview
  • 5.1.2. Management Team
  • 5.1.3. Product Portfolio
    • 5.1.3.1. Lutathera(R)
      • 5.1.3.1.1. Drug Overview
      • 5.1.3.1.2. Clinical Trial Information
      • 5.1.3.1.3. Clinical Trial Results
      • 5.1.3.1.4. Dosing Regimen
    • 5.1.3.2. Pluvicto(R)
      • 5.1.3.2.1. Drug Overview
      • 5.1.3.2.2. Clinical Trial Information
      • 5.1.3.2.3. Clinical Trial Results
      • 5.1.3.2.4. Dosing Regimen
  • 5.1.4. Recent Developments and Future Outlook
• 5.2. Alnylam Pharmaceuticals
  • 5.2.1. Company Overview
  • 5.2.2. Management Team
  • 5.2.3. Product Portfolio
    • 5.2.3.1. Givlaari(R)
      • 5.2.3.1.1. Drug Overview
      • 5.2.3.1.2. Clinical Trial Information
      • 5.2.3.1.3. Clinical Trial Results
      • 5.2.3.1.4. Dosing Regimen
    • 5.2.3.2. Oxlumo(R)
      • 5.2.3.2.1. Drug Overview
      • 5.2.3.2.2. Clinical Trial Information
      • 5.2.3.2.3. Clinical Trial Results
      • 5.2.3.2.4. Dosing Regimen
    • 5.2.3.3. Leqvio(R)
      • 5.2.3.3.1. Drug Overview
      • 5.2.3.3.2. Clinical Trial Information
      • 5.2.3.3.3. Clinical Trial Results
      • 5.2.3.3.4. Dosing Regimen
    • 5.2.3.4. Amvuttra(R)
      • 5.2.3.4.1. Drug Overview
      • 5.2.3.4.2. Clinical Trial Information
      • 5.2.3.4.3. Clinical Trial Results
      • 5.2.3.4.4. Dosing Regimen
  • 5.2.4. Recent Developments and Future Outlook
• 5.3. Arrowhead Pharmaceuticals
  • 5.3.1. Company Overview
  • 5.3.2. Management Team
  • 5.3.3. Product Portfolio
    • 5.3.3.1. Olpasiran
      • 5.3.3.1.1. Drug Overview
      • 5.3.3.1.2. Clinical Trial Information
      • 5.3.3.1.3. Clinical Trial Results
      • 5.3.3.1.4. Dosing Regimen
    • 5.3.3.2. ARO-AAT
      • 5.3.3.2.1. Drug Overview
      • 5.3.3.2.2. Clinical Trial Information
      • 5.3.3.2.3. Clinical Trial Results
      • 5.3.3.2.4. Dosing Regimen
    • 5.3.3.3. ARO-APOC3
      • 5.3.3.3.1. Drug Overview
      • 5.3.3.3.2. Clinical Trial Information
      • 5.3.3.3.3. Clinical Trial Results
      • 5.3.3.3.4. Dosing Regimen
  • 5.3.4. Recent Developments and Future Outlook
• 5.4. Dicerna Pharmaceuticals
  • 5.4.1. Company Overview
  • 5.4.2. Management Team
  • 5.4.3. Product Portfolio
    • 5.4.3.1. Nedosiran
      • 5.4.3.1.1. Drug Overview
      • 5.4.3.1.2. Clinical Trial Information
      • 5.4.3.1.3. Clinical Trial Results
      • 5.4.3.1.4. Dosing Regimen
  • 5.4.4. Recent Developments and Future Outlook
• 5.5. Geron
  • 5.5.1. Company Overview
  • 5.5.2. Management Team
  • 5.5.3. Product Portfolio
    • 5.5.3.1. Imtelstat
      • 5.5.3.1.1. Drug Overview
      • 5.5.3.1.2. Clinical Trial Information
      • 5.5.3.1.3. Clinical Trial Results
      • 5.5.3.1.4. Dosing Regimen
  • 5.5.4. Recent Developments and Future Outlook
• 5.6. Ionis Pharmaceuticals
  • 5.6.1. Company Overview
  • 5.6.2. Management Team
  • 5.6.3. Product Portfolio
    • 5.6.3.1. Eplontersen
      • 5.6.3.1.1. Drug Overview
      • 5.6.3.1.2. Clinical Trial Information
      • 5.6.3.1.3. Clinical Trial Results
      • 5.6.3.1.4. Dosing Regimen
    • 5.6.3.2. Olezarsen
      • 5.6.3.2.1. Drug Overview
      • 5.6.3.2.2. Clinical Trial Information
      • 5.6.3.2.3. Clinical Trial Results
      • 5.6.3.2.4. Dosing Regimen
    • 5.6.3.3. Pelacarsen
      • 5.6.3.3.1. Drug Overview
      • 5.6.3.3.2. Clinical Trial Information
      • 5.6.3.3.3. Clinical Trial Results
      • 5.6.3.3.4. Dosing Regimen
      • 5.6.3.3.5. Estimated Sales
    • 5.6.3.4. Donidalorsen
      • 5.6.3.4.1. Drug Overview
      • 5.6.3.4.2. Clinical Trial Information
      • 5.6.3.4.3. Clinical Trial Results
      • 5.6.3.4.4. Dosing Regimen
  • 5.6.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS

• 6.1. Analysis Methodology and Key Parameters
• 6.2. Next Generation Drug Conjugates: Clinical Trial Analysis
  • 6.2.1. Analysis by Trial Registration Year
  • 6.2.2. Analysis by Trial Phase
  • 6.2.3. Analysis by Trial Status
  • 6.2.4. Analysis by Therapeutic Area
  • 6.2.5. Analysis by Primary Purpose
  • 6.2.6. Analysis by Age Group
  • 6.2.7. Analysis by Type of Sponsor
  • 6.2.8. Most Active Industry Players: Analysis by Number of Trials
  • 6.2.9. Leading Drug Candidates: Analysis by Number of Trials
  • 6.2.10. Analysis by Trial Registration Year and Trial Location
  • 6.2.11. Analysis by Trial Registration Year and Enrolled Patient Population
  • 6.2.12. Analysis by Trial Phase and Enrolled Patient Population
  • 6.2.13. Analysis by Trial Status and Trial Registration Year
  • 6.2.14. Analysis by Trial Location and Enrolled Patient Population
  • 6.2.15. Analysis by Trial Status and Trial Location

7. PARTNERSHIPS AND COLLABORATIONS

• 7.1. Partnership Models
• 7.2. Next Generation Drug Conjugates: Partnerships and Collaborations
  • 7.2.1. Analysis by Year of Partnership
  • 7.2.2. Analysis by Type of Partnership
  • 7.2.3. Analysis by Year and Type of Partnership
  • 7.2.4. Analysis by Type of Partner
  • 7.2.5. Analysis by Year of Partnership and Type of Partner
  • 7.2.6. Analysis by Type of Partnership and Type of Partner
  • 7.2.7. Analysis by Type of Partner and Parent Company Size
  • 7.2.8. Analysis by Therapeutic Area
  • 7.2.9. Most Active Players: Analysis by Number of Partnerships
  • 7.2.10. Analysis by Geography
    • 7.2.10.1. Analysis by Type of Geography (Region-wise)
    • 7.2.10.2. Analysis by Type of Geography (Country-wise)
    • 7.2.10.3. Intercontinental and Intracontinental Agreements

8. ACADEMIC GRANTS ANALYSIS

• 8.1. Methodology and Key Parameters
• 8.2. Next Generation Drug Conjugates: Academic Grants Analysis
  • 8.2.1. Analysis by Year of Grant Award
  • 8.2.2. Analysis by Amount Awarded
  • 8.2.3. Analysis by Funding Institute Center
  • 8.2.4. Analysis by Support Period
  • 8.2.5. Analysis by Funding Institute Center and Support Period
  • 8.2.6. Analysis by Type of Grant Application
  • 8.2.7. Analysis by Purpose of Grant
  • 8.2.8. Analysis by Activity Code
  • 8.2.9. Analysis by Study Section
  • 8.2.10. Popular NIH Departments: Analysis by Number of Grants
  • 8.2.11. Analysis by Type of Recipient Organization
    • 8.2.11.1. Popular Recipient Organizations: Analysis by Number of Grants
    • 8.2.11.2. Popular Recipient Organizations: Analysis by Amount Awarded
  • 8.2.12. Prominent Program Officers: Analysis by Number of Grants
  • 8.2.13. Analysis by Location of Recipient Organizations

9. PUBLICATION ANALYSIS

• 9.1. Analysis Methodology and Key Parameters
• 9.2. Next Generation Drug Conjugates: Publication Analysis
  • 9.2.1. Analysis by Year of Publication
  • 9.2.2. Analysis by Type of Publication
  • 9.2.3. Analysis by Type of Conjugate
  • 9.2.4. Analysis by Target Indication
  • 9.2.5. Analysis by Copyright Holder
  • 9.2.6. Word Cloud: Emerging Focus Area
  • 9.2.7. Most Active Publishers: Analysis by Number of Publications
  • 9.2.8. Key Journals: Analysis by Number of Publications
  • 9.2.9. Key Journals: Analysis by Impact Factor

10. DRUG FAILURE ANALYSIS

• 10.1. Analysis Methodology and Key Parameters
• 10.2. Next Generation Drug Conjugates: Drug Failure Analysis
  • 10.2.1. Analysis by Status of Discontinuation
  • 10.2.2. Analysis by Phase of Discontinuation
  • 10.2.3. Analysis by Average Trial Year
  • 10.2.4. Analysis by Type of Therapy
  • 10.2.5. Analysis by Target Indication
  • 10.2.6. Analysis by Reason for Drug Failure

11. SUCCESS PROTOCOL ANALYSIS

• 11.1. Methodology and Key Parameters
• 11.2. Key Assumptions and Scoring Criteria
• 11.3. Success Protocol Analysis
• 11.4. Assessment of Approved Next Generation Drug Conjugates: Harvey Ball Analysis

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 12.1. Key Assumptions and Forecast Methodology
• 12.2. Next Generation Drug Conjugates Market, till 2035
  • 12.2.1. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate, Current Year and 2035
    • 12.2.1.1. Next Generation Drug Conjugates Market for Peptide Radionuclide Conjugates, till 2035
    • 12.2.1.2. Next Generation Drug Conjugates Market for Ligand Conjugated Anti Sense Medicine, till 2035
    • 12.2.1.3. Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, till 2035
    • 12.2.1.4. Next Generation Drug Conjugates Market for Peptide Drug Conjugates, till 2035
  • 12.2.2. Next Generation Drug Conjugates Market: Distribution by Targeting Ligand
    • 12.2.2.1. Next Generation Drug Conjugates Market for Amino Sugars, till 2035
    • 12.2.2.2. Next Generation Drug Conjugates Market for Peptides, till 2035
    • 12.2.2.3. Next Generation Drug Conjugates Market for Lipids, till 2035
  • 12.2.3. Next Generation Drug Conjugates Market: Distribution by Payload
    • 12.2.3.1. Next Generation Drug Conjugates Market for Radionuclides, till 2035
    • 12.2.3.2. Next Generation Drug Conjugates Market for Drugs, till 2035
    • 12.2.3.3. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, till 2035
    • 12.2.3.4. Next Generation Drug Conjugates Market for si-RNAs, till 2035
  • 12.2.4. Next Generation Drug Conjugates Market: Distribution by Therapy
    • 12.2.4.1. Next Generation Drug Conjugates Market for Monotherapy, till 2035
    • 12.2.4.2. Next Generation Drug Conjugates Market for Combination Therapy, till 2035
  • 12.2.5. Next Generation Drug Conjugates Market: Distribution by Route of Administration
    • 12.2.5.1. Next Generation Intravenous Drug Conjugates Market, till 2035
    • 12.2.5.2. Next Generation Subcutaneous Drug Conjugates Market, till 2035
  • 12.2.6. Next Generation Drug Conjugates Market: Distribution by Target Disease Indication, Current Year and 2035
    • 12.2.6.1. Next Generation Drug Conjugates Market for Gastroenteropancreatic Neuroendocrine Tumors, till 2035
    • 12.2.6.2. Next Generation Drug Conjugates Market for Prostate Cancer, till 2035
    • 12.2.6.3. Next Generation Drug Conjugates Market for Acute Hepatic Porphyria, till 2035
    • 12.2.6.4. Next Generation Drug Conjugates Market for Heterozygous Familial Hypercholesterolemia, till 2035
    • 12.2.6.5. Next Generation Drug Conjugates Market for Hereditary Transthyretin Amyloidosis, till 2035
    • 12.2.6.6. Next Generation Drug Conjugates Market for Primary Hyperoxaluria, till 2035
    • 12.2.6.7. Next Generation Drug Conjugates Market for Leptomeningeal Carcinomatosis, till 2035
    • 12.2.6.8. Next Generation Drug Conjugates Market for Atherosclerotic Cardiovascular Diseases, till 2035
    • 12.2.6.9. Next Generation Drug Conjugates Market for Severe Hypertriglyceridemia, till 2035
    • 12.2.6.10. Next Generation Drug Conjugates Market for Hereditary Angioedema, till 2035
    • 12.2.6.11. Next Generation Drug Conjugates Market for Hemophilia, till 2035
    • 12.2.6.12. Next Generation Drug Conjugates Market for Low-Risk Myelodysplastic Syndrome, till 2035
    • 12.2.6.13. Next Generation Drug Conjugates Market for Myelofibrosis, till 2035
    • 12.2.6.14. Next Generation Drug Conjugates Market for Alpha-1 Antitrypsin Deficiency Liver Disease, till 2035
    • 12.2.6.15. Next Generation Drug Conjugates Market for Familial Chylomicronemia Syndrome, till 2035
    • 12.2.6.16. Next Generation Drug Conjugates Market for Cardiovascular Diseases due to HLP, till 2035
  • 12.2.7. Next Generation Drug Conjugates Market: Distribution by Key Geographical Regions, Current Year and 2035
    • 12.2.7.1. Next Generation Drug Conjugates Market in North America, till 2035
      • 12.2.7.1.1. Next Generation Drug Conjugates Market in the US, till 2035
      • 12.2.7.1.2. Next Generation Drug Conjugates Market in Canada, till 2035
    • 12.2.7.2. Next Generation Drug Conjugates Market in Europe, till 2035
      • 12.2.7.2.1. Next Generation Drug Conjugates Market in France, till 2035
      • 12.2.7.2.2. Next Generation Drug Conjugates Market in the UK, till 2035
      • 12.2.7.2.3. Next Generation Drug Conjugates Market in Germany, till 2035
      • 12.2.7.2.4. Next Generation Drug Conjugates Market in Italy, till 2035
      • 12.2.7.2.5. Next Generation Drug Conjugates Market in Spain, till 2035
      • 12.2.7.2.6. Next Generation Drug Conjugates Market in Rest of the Europe, till 2035
    • 12.2.7.3. Next Generation Drug Conjugates Market in Asia-Pacific, till 2035
      • 12.2.7.3.1. Next Generation Drug Conjugates Market in Japan, till 2035
      • 12.2.7.3.2. Next Generation Drug Conjugates Market in Australia, till 2035
      • 12.2.7.3.3. Next Generation Drug Conjugates Market in Brazil, till 2035
    • 12.2.7.4. Next Generation Drug Conjugates Market in Rest of the World, till 2035
• 12.3. Next Generation Drug Conjugates Market: Product-wise Sales Forecast, till 2035
  • 12.3.1. Lutathera(R)
    • 12.3.1.1. Sales Forecast (USD Million)
  • 12.3.2. Pluvicto(R)
    • 12.3.2.1. Sales Forecast (USD Million)
  • 12.3.3. Givlaari(R)
    • 12.3.3.1. Sales Forecast (USD Million)
  • 12.3.4. Oxlumo(R)
    • 12.3.4.1. Sales Forecast (USD Million)
  • 12.3.5. Leqvio(R)
    • 12.3.5.1. Sales Forecast (USD Million)
  • 12.3.6. Amvuttra(R)
    • 12.3.6.1. Sales Forecast (USD Million)
  • 12.3.7. Eplontersen
    • 12.3.7.1. Sales Forecast (USD Million)
  • 12.3.8. Olezarsen
    • 12.3.8.1. Sales Forecast (USD Million)
  • 12.3.9. Pelacarsen
    • 12.3.9.1. Sales Forecast (USD Million)
  • 12.3.10. Donidalorsen
    • 12.3.10.1. Sales Forecast (USD Million)
  • 12.3.11. Fitusiran
    • 12.3.11.1. Sales Forecast (USD Million)
  • 12.3.12. Nedosiran
    • 12.3.12.1. Sales Forecast (USD Million)
  • 12.3.13. Imetlestat
    • 12.3.13.1. Sales Forecast (USD Million)
  • 12.3.14. Olpasiran
    • 12.3.14.1. Sales Forecast (USD Million)
  • 12.3.15. ARO-AAT
    • 12.3.15.1. Sales Forecast (USD Million)
  • 12.3.16. ARO-APOC3
    • 12.3.16.1. Sales Forecast (USD Million)
  • 12.3.17. ANG-1005
    • 12.3.17.1. Sales Forecast (USD Million)

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료